D. Western Therapeutics Institute, Inc. (FRA:6DW)

Market Cap	30.18M -32.2%
Revenue (ttm)	2.42M -9.4%
Net Income	-6.08M
EPS	-0.14
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.5200
Previous Close	0.5000
Day's Range	0.5200 - 0.5200
52-Week Range	0.4020 - 1.0600
Beta	n/a
RSI	52.82
Earnings Date	Feb 13, 2026

About FRA:6DW

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. The company is also developing DW-5LBT, a lidocain...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 21
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6DW

Financial Performance

In 2024, FRA:6DW's revenue was 471.00 million, an increase of 10.05% compared to the previous year's 428.00 million. Losses were -1.29 billion, 58.9% more than in 2023.

Financial numbers in JPY